Navigation Links
ThermoGenesis Announces Approval of AXP® by India Ministry of Health
Date:1/4/2012

RANCHO CORDOVA, Calif., Jan. 4, 2012 /PRNewswire/ -- ThermoGenesis Corp. (NASDAQ: KOOL), a leading supplier of innovative products and services that process and store adult stem cells, said today that India's Ministry of Health has approved the AutoXpress® System (AXP), enabling the Company to initiate commercial sales of the product in India.  The AXP is used for the processing of stem cells from cord blood.

"We are pleased to have achieved registration for the AXP in India and will be working closely with Fenwal, Inc., our AXP distributor in the market, to begin the commercial launch of the device," said J. Melville Engle, Chairman and Chief Executive Officer of ThermoGenesis.

"The AXP represents advanced stem cell technology and India is one of the largest and fastest-growing markets in the world," said Vikram Karnani, vice president, Therapeutics, for Fenwal.  We look forward to working with ThermoGenesis to introduce this important technology to physicians in India."

Engle noted that the AXP approval in India comes as the Company awaits approval of the product in China. "As we announced in October, the submission has been accepted by the Chinese Food & Drug Administration (SFDA), which represents successful completion of product testing and the administrative acceptance of the submission. The final professional review is now in process and we are hopeful that the AXP will receive regulatory approval in China in early 2012."

About ThermoGenesis Corp.

ThermoGenesis Corp. (www.thermogenesis.com) is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products. These include:

  • The BioArchive® System, an automated cryogenic device, used by cord blood stem cell banks in more than 30 countries for cryopreserving and archiving cord blood stem cell units for transplant.
  • AXP® AutoXpress® Platform (AXP), a proprietary family of automated devices that includes the AXP and the MXP® MarrowXpress® and companion sterile blood processing disposables for harvesting stem cells in closed systems. The AXP device is used for the processing of cord blood. The MXP is used for the preparation of cell concentrates, including stem cells, from bone marrow aspirates in the laboratory setting.
  • The Res-Q® 60 BMC (Res-Q), a point-of-care system designed for the preparation of cell concentrates, including stem cells, from bone marrow aspirates.
  • The CryoSeal® FS System, an automated device and companion sterile blood processing disposable, used to prepare fibrin sealants from plasma in about an hour. The CryoSeal FS System is approved in the U.S. for liver resection surgeries. The CryoSeal FS System has received the CE-Mark which allows sales of the product throughout the European community.

 

This press release contains forward-looking statements.  These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors including timing of FDA and foreign regulatory approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal year 2012, and introduction of competitive products and other factors beyond our control could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2012.  A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.

ThermoGenesis Corp.
Web site: http://www.thermogenesis.com
Contact: Investor Relations
+1-916-858-5107, or
ir@thermogenesis.com


'/>"/>
SOURCE ThermoGenesis Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. ThermoGenesis Announces Acceptance of AXP® Submission by Regulatory Body in China
2. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal 2011 on September 12, 2011
3. ThermoGenesis Announces China Customer Implements Cord Blood Products
4. ThermoGenesis Announces Sale of BioArchive Systems In Asia as Company Increases Presence In Key Market
5. ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line
6. Thermogenesis Corp. to Announce First Quarter Fiscal 2010 Results on November 5, 2009
7. ThermoGenesis Receives Notice Related to Nasdaq Minimum Closing Bid Price Rule
8. ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results
9. ThermoGenesis Announces Expanded Collaboration With Celling Technologies
10. ThermoGenesis Provides Update on Fiscal 2009 Results
11. ThermoGenesis Announces Abstracts to Be Presented at Upcoming Stem Cell Therapy Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... ... August 17, 2017 , ... CNA ... outlet had provided a research update on Aytu Bioscience and cited promising increases ... According to Soulstring, prescription rates for Natesto® have more than doubled since March ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... and Electrospraying line of nanofiber and nanoparticle fabrication instruments ... the lab to fully automated pilot plants and equipment for industrial manufacturing. ...
(Date:8/16/2017)... ... 16, 2017 , ... Today, 3Bar Biologics Inc ., ... in funding from an impressive group of investors, including Rev1 Ventures, Maumee Ventures, ... this investment, 3Bar is broadening availability of its groundbreaking offering that uses naturally ...
(Date:8/16/2017)... BOSTON and OXFORD, England , ... -based consortium for biotech executive search and leadership development, ... and Healthcare sectors, have created an exclusive alliance that enables ... "For our clients here ... collaboration provides unparalleled access to a diverse population of leadership ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 5, 2017 Today ... announcing that the server component of the HYPR platform ... for providing the end-to-end security architecture that empowers biometric ... HYPR has already secured over 15 million users ... including manufacturers of connected home product suites and physical ...
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
(Date:3/30/2017)... March 30, 2017 Trends, opportunities and forecast ... behavioral), by technology (fingerprint, AFIS, iris recognition, facial recognition, ... others), by end use industry (government and law enforcement, ... and banking, and others), and by region ( ... Asia Pacific , and the Rest ...
Breaking Biology News(10 mins):